Antibodies and fv fragment recognizing antigen ior c2
The invention relates to the obtention of novel recombinant antibodies from murine antibody IOR C5 produced by the hybridoma deposited with the ECCC 97061101 according to the Budapest Treaty. Said recombinant antibodies were obtained using recombinant DNA technology and are characterized in that the...
Saved in:
Main Authors | , , , , , , , , , , |
---|---|
Format | Patent |
Language | English |
Published |
30.05.2001
|
Edition | 7 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The invention relates to the obtention of novel recombinant antibodies from murine antibody IOR C5 produced by the hybridoma deposited with the ECCC 97061101 according to the Budapest Treaty. Said recombinant antibodies were obtained using recombinant DNA technology and are characterized in that they recognize antigen ior C2. The recombinant antibodies are specifically chimeric antibody, humanized antibody, and single chain Fv fragment. The chimeric antibody contains the variable domains of the murine immunoglobuline and the constant regions of the human immunoglobuline. The humanized antibody contains the constant regions of human immunoglobuline and has been specifically modified in the murine frameworks regions (FRs) and within the latter, in those areas that may result in an antigenic site for cells T. The Fv fragment contains the variable domains of murine immunoglobuline. The invention also relates to the utilization of recombinant antibodies derived from murine antibody ior C5 in the diagnosis and therapy of colorectal tumors, the metastasis thereof and recurrences. |
---|---|
Bibliography: | Application Number: AU1513001 |